Daxor CORP 8-K filings

Daxor Corporation shareholders re-elected six directors and ratified the appointment of their independent auditor at the 2026 Annual Meeting.

Daxor Corporation completed a registered direct offering, raising approximately $8.14 million in net proceeds through the sale of 765,958 common shares at $11.75 each.

Daxor Corporation has filed its current investor presentation as an exhibit to a Form 8-K, making it available to investors.

Daxor Corporation announced FDA 510(k) clearance for its next-generation rapid, portable lab-based Blood Volume Analysis (BVA) system, poised to significantly improve patient outcomes.

Daxor Corporation announced the results of its Annual Meeting held on June 24, 2025, confirming the re-election of all six directors and the ratification of Bush & Associates, CPA as its independent registered public accounting firm.

Daxor Corporation held its annual meeting on July 15, 2024, electing directors and ratifying its independent auditor.

Daxor Corporation has regained compliance with Nasdaq listing rules after appointing a new member to its audit committee, resolving a previous non-compliance issue.

Daxor Corporation has acquired exclusive rights to manufacture Volumex and Megatope, and the exclusive rights to sell Glofil, expanding its diagnostic offerings and aiming for immediate cash flow positivity.